Breakthroughs in Cancer Gene Therapy: Enhancing NK Cell Antitumor Function

Researchers in Shanghai have made significant strides in cancer gene therapy by harnessing the power of natural killer (NK) cells. According to a recent study published in Critical Reviews In Oncology Hematology, genetic engineering strategies have been optimized to enhance NK cell antitumor function, offering new hope for cancer treatment. The review highlights the recent advances in chimeric antigen receptors (CARs) specifically designed for NK cells, immune checkpoint resistance, metabolic reprogramming, and cytokine support to improve survival and potency. By combining these strategies with monoclonal antibodies, oncolytic viruses, vaccines, and adoptive immune cell therapy, researchers are poised to transition NK-based therapies from supportive to frontline modalities in cancer treatment.

Key Takeaways:

• Researchers have identified the limitations of NK cells in cancer treatment, including poor in vivo persistence, inadequate tumor infiltration, and suppression by the immunosuppressive tumor microenvironment (TME).
• Genetic engineering strategies have been developed to enhance NK cell antitumor function, including optimization of CARs specifically for NK cells and incorporation of immune checkpoint resistance.
• Combination strategies with monoclonal antibodies, oncolytic viruses, vaccines, and adoptive immune cell therapy have shown promise in synergizing with NK cells.
• Innovative platforms such as nanoparticle delivery systems and NK cell-derived exosomes are being explored to further enhance therapeutic outcomes.
• The study provides a comprehensive roadmap for the next generation of NK cell therapies with broad translational potential.
• Researchers from the Research and Development Department at Shanghai Unicar Therapy Bio-Medicine Technology Co., Ltd. are leading the charge in developing NK-based therapies.

Statistics:

• The study highlights the potential of NK cells in cancer treatment, with a focus on enhancing antitumor function and improving survival and potency.
• The researchers have explored various genetic engineering strategies to optimize CAR design, immune checkpoint resistance, and metabolic reprogramming, with a focus on improving NK cell performance.
• The study concludes that by systematically addressing the limitations of NK cells through genetic precision and combinatorial immunomodulation, NK-based therapies are poised to transition from supportive to frontline modalities in cancer treatment.

Sources:

• Research and Development Department, Shanghai Unicar Therapy Bio-Medicine Technology Co., Ltd.
• Critical Reviews In Oncology Hematology (2025:104972)
• Elsevier Science Inc (Ste 800, 230 Park Ave, New York, NY 10169, USA)
• Israth Jahan Tuhin, Researcher, Research and Development Department, Shanghai Unicar Therapy Bio-Medicine Technology Co., Ltd.
• Additional authors: Hong Jia Zhu, Masuma Akter Monty, Jin Wen Tan, Nan Xu, Jing Ye, and Lei Yu.